Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gynecologic 3Genitourinary 1Gastrointestinal 1

Conditions

Oropharyngeal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × MEDI0457 × Head & Neck × Clear all
NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04001413 2022-07-29

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms

NCT02163057 2021-01-22

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Inovio Pharmaceuticals

Phase 1/2 Completed
22 enrolled 14 charts
Head & Neck

Head and Neck Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡